-
NMPA Issues the Announcement on the Requirements for the Management of Drug Records and Data (Interim)
2020-06-24
NMPA has organized to formulate the Requirements for the Management of Drug Records and Data (Interim), which was issued on June 24, 2020 and shall come into force as of December 1, 2020.
-
NMPA Issues the Announcement on Upgrading Related Systems for Drug Registration
2020-06-17
To support the implementation of the newly revised Provisions for Drug Registration, NMPA is currently stepping up the upgrade of related systems for drug registration.
-
NMPA Issues Announcement on Revising Package Insert of Vitamin B2 Injection
2020-06-11
On June 11, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [contraindications], etc. in the package insert of Vitamin B2 Injection.
-
NMPA Issues Announcement on Revising Package Insert of Sodium Thiosulfate Injection
2020-06-11
On June 11, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions], etc. in the package insert of Sodium Thiosulfate Injection.
-
NMPA Issues Announcement on Revising Package Insert of Posterior Pituitary Injection
2020-06-09
On June 9, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions], etc. in the package insert of Posterior Pituitary Injection.
-
NMPA Issues Announcement on Revising Package Inserts of Chuanbei Pipa Preparations
2020-06-09
NMPA issued an Announcement on June 9, 2020, with decisions made to uniformly revise the [adverse reactions], [contraindications] and [precautions] in the package inserts of Chuanbei Pipa Preparations (including syrups, ointments, granules, tablets and capsules).